ReviewDrugs2019
Advances in Targeted Therapies for Triple-Negative Breast Cancer.
Review in Drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Research advances in aptamers in the diagnosis and treatment of breast cancer (Review).International journal of oncology · 2026Review
- Ginger-derived 1-(4'-hydroxy-3'-methoxyphenyl)-5-methoxydecan-3-one (HMPM) induces apoptosis and DNA damage against triple-negative breast cancer cells in vitro.Molecular biology reports · 2025Article
- A coagulation-related long non-coding RNA signature to predict prognosis and immune features of breast cancer.Discover oncology · 2025Article
- Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer.Science advances · 2024Article
- Alkaloids as Additional Weapons in the Fight against Breast Cancer: A Review.Current medicinal chemistry · 2024Review
- Preliminary evaluation of deep learning for first-line diagnostic prediction of tumor mutational status.Scientific reports · 2023Article
- Article
- Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment.Scientific reports · 2023Article
- Ginger-Derived 3HDT Exerts Antiproliferative Effects on Breast Cancer Cells by Apoptosis and DNA Damage.International journal of molecular sciences · 2023Article
- m6A readers, writers, erasers, and the m6A epitranscriptome in breast cancer.Journal of molecular endocrinology · 2023Review
- Marine SpongePharmaceuticals (Basel, Switzerland) · 2022Article
- Evaluating the Accuracy of FUCCI Cell Cycle In Vivo Fluorescent Imaging to Assess Tumor Proliferation in Preclinical Oncology Models.Molecular imaging and biology · 2022Article
- Physapruin A Induces Reactive Oxygen Species to Trigger Cytoprotective Autophagy of Breast Cancer Cells.Antioxidants (Basel, Switzerland) · 2022Article
- Screening of Specific and Common Pathways in Breast Cancer Cell Lines MCF-7 and MDA-MB-231 Treated with Chlorophyllides Composites.Molecules (Basel, Switzerland) · 2022Article
- Sociodemographic disparities in molecular testing for breast cancer.Cancer causes & control : CCC · 2022Article
- Aptamer-armed nanostructures improve the chemotherapy outcome of triple-negative breast cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC).Pharmaceuticals (Basel, Switzerland) · 2022Review
- Computationally repurposing drugs for breast cancer subtypes using a network-based approach.BMC bioinformatics · 2022Article
- MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer.Molecular cancer research : MCR · 2022Article
- Density-Dependent Migration Characteristics of Cancer Cells Driven by Pseudopod Interaction.Frontiers in cell and developmental biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While the outcomes for patients diagnosed with hormone receptor positive (HR+) and/or human epidermal growth factor receptor 2-positive (HER2+) breast cancers have continued to improve with the development of targeted therapies, the same cannot be said yet for those affected with triple-negative breast cancer (TNBC). Currently, the mainstay of treatment for the 10-15% of patients diagnosed with TNBC remains cytotoxic chemotherapy, but it is hoped that through an enhanced characterization of TNBC biology, this disease will be molecularly delineated into subgroups with targetable oncogenic drivers. This review will focus on recent therapeutic innovations for TNBC, including poly-ADP-ribosyl polymerase (PARP) inhibitors, phosphoinositide 3-kinase (PI3K) pathway inhibitors, immune checkpoint inhibitors, and cyclin-dependent kinase (CDK) inhibitors.
Indexed as
Identifiers
31254268What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.